Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 3, p.437-44 (2010)


2010, Adult, Aged, Aged, 80 and over, Center-Authored Paper, Female, Hematologic Agents, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Receptors, Fc, Recombinant Fusion Proteins, Thrombocytopenia, Thrombopoietin, Treatment Outcome


To assess the safety and efficacy of romiplostim, a peptibody that increases platelet production, for treatment of thrombocytopenic patients with myelodysplastic syndromes (MDS).